Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
316.27
-0.56 (-0.18%)
At close: Nov 12, 2026, 4:00 PM EST
317.00
+0.73 (0.23%)
After-hours: Nov 12, 2026, 7:59 PM EST
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 47 employees as of December 31, 2025. The number of employees decreased by 21 or 30.88% compared to the previous year. That makes Ligand Pharmaceuticals the 35,297th largest employer in the world and 4,725th in the United States.
Employees
47
Change (1Y)
-21
Growth (1Y)
-30.88%
Revenue / Employee
$5,400,574
Profits / Employee
$1,094,936
Market Cap
6.33B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 47 | -21 | -30.88% |
| Dec 31, 2024 | 68 | 10 | 17.24% |
| Dec 31, 2023 | 58 | -18 | -23.68% |
| Dec 31, 2022 | 76 | -78 | -50.65% |
| Dec 31, 2021 | 154 | -1 | -0.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Mirum Pharmaceuticals | 470 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
LGND News
- 1 day ago - Ligand price target raised to $350 from $345 at Barclays - TheFly
- 7 days ago - Ligand price target raised to $402 from $397 at Citi - TheFly
- 13 days ago - Ligand price target raised to $346 from $334 at Oppenheimer - TheFly
- 13 days ago - Ligand price target raised to $350 from $332 at Stifel - TheFly
- 14 days ago - Ligand Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 14 days ago - Ligand Pharmaceuticals Earnings release: Q3 2026 - Filings
- 14 days ago - Ligand Pharmaceuticals Slides: Q3 2026 - Filings
- 14 days ago - Ligand Pharmaceuticals Quarterly report: Q3 2026 - Filings